Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.64 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 6/20 | 0.49 |
| ▸ | DBF4 | Q9UBU7 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886595 | 0.83 | TRPM8 (0.71) | TRPM8MAPTPTPN11GAAKMT2A | |
| SCHEMBL31301381 | 0.83 | SMN1; SMN2 (0.57) | TRPM8MAPTPTPN11GAAKMT2A | |
| SCHEMBL2576628 | 0.82 | TRPM8 (0.70) | TRPM8MAPTPTPN11GAAKMT2A | |
| SCHEMBL5937272 | 0.81 | PTPN11 (0.72) | TRPM8MAPTPTPN11GAAKMT2A | |
| SCHEMBL2885708 | 0.80 | TRPM8 (0.78) | TRPM8MAPTPTPN11GAAKMT2A | |
| SCHEMBL12475538 | 0.79 | PTPN11 (0.60) | TRPM8MAPTPTPN11GAAKMT2A | |
| SCHEMBL15048955 | 0.79 | TRPM8 (1.00) | TRPM8MAPTPTPN11KMT2AMEN1 | |
| SCHEMBL2883593 | 0.79 | TRPM8 (0.55) | TRPM8MAPTPTPN11GAAKMT2A | |
| SCHEMBL622760 | 0.78 | CDC7 (0.70) | TRPM8MAPTPTPN11CDC7DBF4 | |
| SCHEMBL12475713 | 0.78 | TRPM8 (0.70) | TRPM8MAPTPTPN11GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | TRPM8 2262/4885MAPT 4575/4885PTPN11 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.